Antiretroviral therapy: The "when to start" debates

被引：9

作者：

Cohen, CJ

Boyle, BA

机构：

[1] Harvard Vanguard Med Associates, CRI New England, Boston, MA 02215 USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

[3] Cornell Univ, Weill Med Coll, New York, NY USA

来源：

CLINICAL INFECTIOUS DISEASES | 2004年 / 39卷 / 11期

关键词：

D O I：

10.1086/425934

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：1705 / 1708

页数：4

共 20 条

[1] Correlation between breadth of memory HIV-specific cytotoxic T cells, viral load and disease progression in HIV infection [J].

Chouquet, C ;

Autran, B ;

Gomard, E ;

Bouley, JM ;

Calvez, V ;

Katlama, C ;

Costagliola, D ;

Rivière, Y .

AIDS, 2002, 16 (18) :2399-2407

[2] Combination antiretroviral therapy and the risk of myocardial infarction [J].

Friis-Moller, N ;

Sabin, CA ;

Weber, R ;

Monforte, AD ;

El-Sadr, WM ;

Reiss, P ;

Thiébaut, R ;

Morfeldt, L ;

De Wit, S ;

Pradier, C ;

Calvo, G ;

Law, MG ;

Kirk, O ;

Phillips, AN ;

Lundgren, JD ;

Weber, R ;

Monteforte, AD ;

Bartsch, G ;

Reiss, P ;

Dabis, F ;

Morfeldt, L ;

De Wit, S ;

Pradier, C ;

Calvo, G ;

Law, MG ;

Kirk, O ;

Phillips, AN ;

Houyez, F ;

Loeliger, E ;

Tressler, R ;

Weller, I ;

Friis-Moller, N ;

Sabin, CA ;

Sjol, A ;

Lundgren, JD ;

Sawitz, A ;

Rickenbach, M ;

Pezzotti, P ;

Krum, E ;

Meester, R ;

Lavignolle, V ;

Sundström, A ;

Poll, B ;

Fontas, E ;

Torres, F ;

Petoumenos, K ;

Kjær, J ;

Hammer, S ;

Neaton, J .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003

[3]

FriisMoller N, 2004, NEW ENGL J MED, V350, P955

[4] Efficacy and safety of tenofovir DF vs stavuldine in combination therapy in antiretroviral-naive patients - A 3-year randomized trial [J].

Gallant, JE ;

Staszewski, S ;

Pozniak, AL ;

DeJesus, E ;

Suleiman, JMAH ;

Miller, MD ;

Coakley, DF ;

Lu, B ;

Toole, JJ ;

Cheng, AK .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (02) :191-201

[5] SOLO:: 48-week efficacy and safety comparison of once-daily fosamprenavir/ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients [J].

Gathe, JC ;

Ive, P ;

Wood, R ;

Schürmann, D ;

Bellos, NC ;

DeJesus, E ;

Gladysz, A ;

Garris, C ;

Yeo, J .

AIDS, 2004, 18 (11) :1529-1537

[6] TIME TO HIT HIV, EARLY AND HARD [J].

HO, DD .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (07) :450-451

[7] Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy [J].

Hogg, RS ;

Yip, B ;

Chan, KJ ;

Wood, E ;

Craib, KJP ;

O'Shaughnessy, MV ;

Montaner, JSG .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2568-2577

[8] The case for earlier treatment of HIV infection [J].

Holmberg, SD ;

Palella, FJ ;

Lichtenstein, KA ;

Havlir, DV .

CLINICAL INFECTIOUS DISEASES, 2004, 39 (11) :1699-1704

[9] Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy [J].

Kirk, O ;

Reiss, P ;

Uberti-Foppa, C ;

Bickel, M ;

Gerstoft, J ;

Pradier, C ;

Wit, FW ;

Ledergerber, B ;

Lundgren, JD ;

Furrer, H ;

Seven European HIV Cohorts .

ANNALS OF INTERNAL MEDICINE, 2002, 137 (04) :239-250

[10] Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy [J].

Kroon, FP ;

Rimmelzwaan, GF ;

Roos, MTL ;

Osterhaus, AME ;

Hamann, D ;

Miedema, F ;

van Dissel, JT .

AIDS, 1998, 12 (17) :F217-F223

← 1 2 →